NAFLD Fibrosis Score (NFS)
NFS and FIB-4 are validated non-invasive tools to identify advanced liver fibrosis in NAFLD, reducing the need for liver biopsy.
Why This Health Metric Matters
Why: Advanced fibrosis (F3-F4) predicts cirrhosis and liver-related outcomes. Non-invasive scores help stratify who needs further testing.
How: Enter age, BMI, diabetes status, AST, ALT, platelets, albumin. NFS and FIB-4 formulas combine these into risk categories.
- ●NFS < -1.455: low risk
- ●NFS > 0.676: high risk
- ●Use with FIB-4 for best accuracy
Sample Clinical Scenarios
🟢 Low Risk
Normal liver enzymes, no diabetes
🟡 Intermediate
Elevated enzymes, prediabetes
🔴 High Risk
Diabetic with elevated AST/ALT
🏋️ Obese NAFLD
Metabolic syndrome
📊 Lean NAFLD
Normal BMI with NAFLD
Enter Patient Data
⚠️For informational purposes only — not medical advice. Consult a healthcare professional before acting on results.
🏥 Health Facts
Non-invasive fibrosis assessment
— Clinical
Validated in NAFLD
— Research
Understanding NAFLD Fibrosis Scoring
The NAFLD Fibrosis Score (NFS) and FIB-4 are validated non-invasive tools to identify patients with advanced fibrosis (F3-F4), reducing the need for liver biopsy.
Low Risk
NFS < -1.455
FIB-4 < 1.3
Advanced fibrosis unlikely
Intermediate
NFS -1.455 to 0.676
FIB-4 1.3 to 2.67
Further testing needed
High Risk
NFS > 0.676
FIB-4 > 2.67
Advanced fibrosis likely